SCM
Sarissa Capital Management Portfolio holdings
AUM
$154M
This Quarter Return
+9.16%
1 Year Return
-6.05%
3 Year Return
-7.91%
5 Year Return
+32.47%
10 Year Return
+262.41%
AUM
$290M
AUM Growth
+$290M
(+8.8%)
Cap. Flow
+$8.01M
Cap. Flow
% of AUM
2.76%
Top 10 Holdings %
Top 10 Hldgs %
96.57%
Holding
18
New
6
Increased
3
Reduced
1
Closed
3
Top Buys
| 1 |
BRLI
BIO-REFERENCE LABS INC-NEW-
BRLI
|
$27.6M |
| 2 |
Quest Diagnostics
DGX
|
$4.34M |
| 3 |
Labcorp
LH
|
$3.72M |
| 4 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$2.3M |
| 5 |
Traws Pharma
TRAW
|
$2.22M |
Top Sells
| 1 |
Bristol-Myers Squibb
BMY
|
$13.3M |
| 2 |
AbbVie
ABBV
|
$13.2M |
| 3 |
Pfizer
PFE
|
$12.6M |
| 4 |
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
|
$324K |
Sector Composition
| 1 | Healthcare | 76.66% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ARIA
1
DELISTED
Ariad Pharmaceuticals Inc
ARIA
| $96.7M | 33.3% | 12,000,000 | – | – |
|
|
2
Quest Diagnostics
DGX
$20.3B
| $44.9M | 15.46% | 775,000 +75,000 | +11% | +$4.34M |
|
|
BRLI
3
DELISTED
BIO-REFERENCE LABS INC-NEW-
BRLI
| $35.5M | 12.21% | 1,280,984 +995,684 | +349% | +$27.6M |
|
|
IDIX
4
DELISTED
IDENIX PHARMACEUTICALS INC
IDIX
| $30.5M | 10.49% | 5,050,100 | – | – |
|
5
Merck
MRK
$210B
| $22.7M | 7.82% | 400,000 | – | – |
|
|
MNK
6
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $17.4M | 6% | 274,895 -5,105 | -2% | -$324K |
|
|
VVUS
7
DELISTED
Vivus Inc
VVUS
| $15.3M | 5.26% | 2,573,943 | – | – |
|
|
RPRX
8
DELISTED
Repros Therapeutics Inc.
RPRX
| $9.95M | 3.42% | 560,600 +101,092 | +22% | +$1.79M |
|
|
AVEO
9
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
| $3.84M | 1.32% | 2,570,759 | – | – |
|
|
10
Labcorp
LH
$23.1B
| $3.72M | 1.28% | +37,824 | New | +$3.72M |
|
|
ITCI
11
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $2.3M | 0.79% | +126,695 | New | +$2.3M |
|
|
12
Traws Pharma
TRAW
$9.89M
| $2.22M | 0.76% | +350,000 | New | +$2.22M |
|
13
Enanta Pharmaceuticals
ENTA
$180M
| $2M | 0.69% | +50,000 | New | +$2M |
|
|
KIN
14
DELISTED
Kindred Biosciences, Inc.
KIN
| $1.89M | 0.65% | +101,825 | New | +$1.89M |
|
15
Gyre Therapeutics
GYRE
$703M
| $1.57M | 0.54% | +329,516 | New | +$1.57M |
|
|
16
AbbVie
ABBV
$372B
| – | – | -250,000 | Closed | -$13.2M |
|
|
17
Bristol-Myers Squibb
BMY
$96B
| – | – | -250,000 | Closed | -$13.3M |
|
|
18
Pfizer
PFE
$141B
| – | – | -410,000 | Closed | -$12.6M |
|